328 related articles for article (PubMed ID: 24885928)
1. Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1.
Weygant N; Qu D; Berry WL; May R; Chandrakesan P; Owen DB; Sureban SM; Ali N; Janknecht R; Houchen CW
Mol Cancer; 2014 May; 13():103. PubMed ID: 24885928
[TBL] [Abstract][Full Text] [Related]
2. Biochemical and Structural Insights into Doublecortin-like Kinase Domain 1.
Patel O; Dai W; Mentzel M; Griffin MD; Serindoux J; Gay Y; Fischer S; Sterle S; Kropp A; Burns CJ; Ernst M; Buchert M; Lucet IS
Structure; 2016 Sep; 24(9):1550-61. PubMed ID: 27545623
[TBL] [Abstract][Full Text] [Related]
3. Structural Basis of Inhibition of DCLK1 by Ruxolitinib.
Jang DM; Lim HJ; Hahn H; Lee Y; Kim HK; Kim HS
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445192
[TBL] [Abstract][Full Text] [Related]
4. Doublecortin-Like Kinase 1 (DCLK1) Regulates B Cell-Specific Moloney Murine Leukemia Virus Insertion Site 1 (Bmi-1) and is Associated with Metastasis and Prognosis in Pancreatic Cancer.
Li J; Wang Y; Ge J; Li W; Yin L; Zhao Z; Liu S; Qin H; Yang J; Wang L; Ni B; Liu Y; Wang H
Cell Physiol Biochem; 2018; 51(1):262-277. PubMed ID: 30453285
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of cytotoxic effects of gemcitabine by Dclk1 inhibition through suppression of Chk1 phosphorylation in human pancreatic cancer cells.
Kawamura D; Takemoto Y; Nishimoto A; Ueno K; Hosoyama T; Shirasawa B; Tanaka T; Kugimiya N; Harada E; Hamano K
Oncol Rep; 2017 Nov; 38(5):3238-3244. PubMed ID: 29048622
[TBL] [Abstract][Full Text] [Related]
6. Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer.
Ge Y; Weygant N; Qu D; May R; Berry WL; Yao J; Chandrakesan P; Zheng W; Zhao L; Zhao KL; Drake M; Vega KJ; Bronze MS; Tomasek JJ; An G; Houchen CW
Int J Cancer; 2018 Sep; 143(5):1162-1175. PubMed ID: 29577277
[TBL] [Abstract][Full Text] [Related]
7. XMD8-92 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanism.
Sureban SM; May R; Weygant N; Qu D; Chandrakesan P; Bannerman-Menson E; Ali N; Pantazis P; Westphalen CB; Wang TC; Houchen CW
Cancer Lett; 2014 Aug; 351(1):151-61. PubMed ID: 24880079
[TBL] [Abstract][Full Text] [Related]
8. Repurposing diacerein to suppress colorectal cancer growth by inhibiting the DCLK1/STAT3 signaling pathway.
Ye Q; Zhu Y; Shi M; Lv L; Gong Y; Zhang L; Yang L; Zhao H; Zhao C; Xu H
Chin J Nat Med; 2024 Apr; 22(4):318-328. PubMed ID: 38658095
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of LEF1-Mediated DCLK1 by Niclosamide Attenuates Colorectal Cancer Stemness.
Park SY; Kim JY; Choi JH; Kim JH; Lee CJ; Singh P; Sarkar S; Baek JH; Nam JS
Clin Cancer Res; 2019 Feb; 25(4):1415-1429. PubMed ID: 30446587
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of doublecortin-like kinase 1 inhibitors and their bioactivity evaluation.
Pan P; Ji D; Li Z; Meng X
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2287990. PubMed ID: 38062554
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a selective inhibitor of doublecortin like kinase 1.
Ferguson FM; Nabet B; Raghavan S; Liu Y; Leggett AL; Kuljanin M; Kalekar RL; Yang A; He S; Wang J; Ng RWS; Sulahian R; Li L; Poulin EJ; Huang L; Koren J; Dieguez-Martinez N; Espinosa S; Zeng Z; Corona CR; Vasta JD; Ohi R; Sim T; Kim ND; Harshbarger W; Lizcano JM; Robers MB; Muthaswamy S; Lin CY; Look AT; Haigis KM; Mancias JD; Wolpin BM; Aguirre AJ; Hahn WC; Westover KD; Gray NS
Nat Chem Biol; 2020 Jun; 16(6):635-643. PubMed ID: 32251410
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-195 Suppresses the Progression of Pancreatic Cancer by Targeting DCLK1.
Zhou B; Sun C; Hu X; Zhan H; Zou H; Feng Y; Qiu F; Zhang S; Wu L; Zhang B
Cell Physiol Biochem; 2017; 44(5):1867-1881. PubMed ID: 29224010
[TBL] [Abstract][Full Text] [Related]
13. Targeting DCLK1 overcomes 5-fluorouracil resistance in colorectal cancer through inhibiting CCAR1/β-catenin pathway-mediated cancer stemness.
Wang L; Zhao L; Lin Z; Yu D; Jin M; Zhou P; Ren J; Cheng J; Yang K; Wu G; Zhang T; Zhang D
Clin Transl Med; 2022 May; 12(5):e743. PubMed ID: 35522902
[TBL] [Abstract][Full Text] [Related]
14. DCLK1 inhibition attenuates tumorigenesis and improves chemosensitivity in esophageal squamous cell carcinoma by inhibiting β-catenin/c-Myc signaling.
Zhang L; Zhou S; Guo E; Chen X; Yang J; Li X
Pflugers Arch; 2020 Aug; 472(8):1041-1049. PubMed ID: 32533239
[TBL] [Abstract][Full Text] [Related]
15. DCLK1 is a broadly dysregulated target against epithelial-mesenchymal transition, focal adhesion, and stemness in clear cell renal carcinoma.
Weygant N; Qu D; May R; Tierney RM; Berry WL; Zhao L; Agarwal S; Chandrakesan P; Chinthalapally HR; Murphy NT; Li JD; Sureban SM; Schlosser MJ; Tomasek JJ; Houchen CW
Oncotarget; 2015 Feb; 6(4):2193-205. PubMed ID: 25605241
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of novel DCLK1 inhibitor containing purine skeleton for the treatment of pancreatic cancer.
Chen Y; Meng L; Wang W; Ye L; Huang L; Wang C; Wang S; Li M; Pei Y; Zhang S; Zou Y; Xu Y
Eur J Med Chem; 2023 Dec; 261():115846. PubMed ID: 37862816
[TBL] [Abstract][Full Text] [Related]
17. Dclk1 Inhibition Cancels 5-FU-induced Cell-cycle Arrest and Decreases Cell Survival in Colorectal Cancer.
Suehiro Y; Takemoto Y; Nishimoto A; Ueno K; Shirasawa B; Tanaka T; Kugimiya N; Suga A; Harada E; Hamano K
Anticancer Res; 2018 Nov; 38(11):6225-6230. PubMed ID: 30396941
[TBL] [Abstract][Full Text] [Related]
18. [Doublecortin-like kinase 1 activates Hippo pathway to promote migration, invasion and proliferation of pancreatic cancer cells].
Yan R; Liang ZW; Liu HS; Ge Y; An GY
Zhonghua Zhong Liu Za Zhi; 2023 Jul; 45(7):594-604. PubMed ID: 37462016
[No Abstract] [Full Text] [Related]
19. Targeting doublecortin-like kinase 1 reveals a novel strategy to circumvent chemoresistance and metastasis in ovarian cancer.
Dogra S; Elayapillai SP; Qu D; Pitts K; Filatenkov A; Houchen CW; Berry WL; Moxley K; Hannafon BN
Cancer Lett; 2023 Dec; 578():216437. PubMed ID: 37838282
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-424 inhibits cell migration, invasion, and epithelial mesenchymal transition by downregulating doublecortin-like kinase 1 in ovarian clear cell carcinoma.
Wu X; Ruan Y; Jiang H; Xu C
Int J Biochem Cell Biol; 2017 Apr; 85():66-74. PubMed ID: 28161486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
